



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 6/14/06

Signature: *D. Class*

Docket No.: VASG-P01-002  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Krasnoperov et al.

Application No.: 10/800350

Confirmation No.: 2293

Filed: March 12, 2004

Art Unit: 1642

For: POLYPEPTIDE COMPOUNDS FOR  
INHIBITING ANGIOGENESIS AND  
TUMOR GROWTH

Examiner: S. E. Aeder

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Applicants have not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicants submit herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).


In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 18-1945 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. VASG-P01-002. A duplicate copy of this paper is enclosed.

Dated: June 14, 2006

Respectfully submitted,

By 

Z. Angela Guo

Registration No.: 54,144

FISH & NEAVE IP GROUP, ROPES & GRAY  
LLP

One International Place  
Boston, Massachusetts 02110-2624  
(617) 951-7000  
(617) 951-7050 (Fax)  
Attorneys/Agents For Applicants



PTO/SB/08a/b (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |                          |                        |              |
|--|---|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/B/PTO  |   |    | <b>Complete if Known</b> |                        |              |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    | Application Number       | 10/800350              |              |
|  |   |    | Filing Date              | March 12, 2004         |              |
|  |   |    | First Named Inventor     | Valery Krasnoperov     |              |
|  |   |    | Art Unit                 | 1642                   |              |
|  |   |    | Examiner Name            | S. E. Aeder            |              |
| Sheet  | 1 | of | 6                        | Attorney Docket Number | VASG-P01-002 |

| U.S. PATENT DOCUMENTS |                       |  |                                |  |   |
|-----------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials*    | Cite No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|                       |                       | Number-Kind Code <sup>2</sup> (if known) |                                |  |   |
|                       | AE                    | US-2002/0136726                          | 09-26-2002                     | Anderson et al.                                    |   |
|                       | AF                    | US-5,824,303                             | 10-20-1998                     | Bartley et al.                                     |   |
|                       | AG                    | US-6,514,497                             | 02-04-2003                     | Briskin et al.                                     |   |
|                       | AH                    | US-5,795,734                             | 08-18-1998                     | Flanagan et al.                                    |   |
|                       | AI                    | US-5,770,599                             | 06-23-1998                     | Gibson   |   |
|                       | AJ                    | US-6,440,954                             | 08-27-2002                     | Haber et al.                                       |   |
|                       | AK                    | US-5,512,591                             | 04-30-1996                     | Halperin et al.                                    |   |
|                       | AL                    | US-6,015,711                             | 01-18-2000                     | Olson et al.                                       |   |
|                       | AM                    | US-6,579,683                             | 06-17-2003                     | Wang et al.  |   |
|                       | AN                    | US-6,887,674                             | 05-03-2005                     | Wang et al.  |   |
|                       | AO                    | US-6,916,625                             | 07-12-2005                     | Wang et al.  |   |
|                       | AP                    | US-2005/0204412                          | 09-15-2005                     | Wang et al.  |   |
|                       | AQ                    | US-6,864,227                             | 03-08-2005                     | Wang et al.  |   |
|                       | AR                    | US-2006/0035328                          | 02-16-2006                     | Wang et al.  |   |

| FOREIGN PATENT DOCUMENTS |                       |   |                                |   |   |                |
|--------------------------|-----------------------|---|--------------------------------|---|---|----------------|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T <sup>6</sup> |
|                          |                       | Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known) |                                |   |   |                |
|                          | BV                    | WO 98/43960   | 10-08-1998                     | American Cyanamid Company                       |   |                |
|                          | BW                    | WO 94/11020   | 05-26-1994                     | Amgen Inc.                                      |   |                |
|                          | BX                    | WO 96/23000   | 08-01-1996                     | Amgen Inc.                                      |   |                |
|                          | BY                    | WO 96/36713   | 11-21-1996                     | Amgen Inc.                                      |   |                |
|                          | BZ                    | WO 97/23629   | 07-03-1997                     | Amrad Operations PTY. Ltd.                      |   |                |
|                          | BA1                   | EP 633 315-A2   | 01-11-1995                     | C.I.E.M.A.T.                                    |   |                |
|                          | BB1                   | WO 99/52541   | 10-21-1999                     | California Institute of Technology              |   |                |
|                          | BC1                   | WO 98/45331   | 10-15-1998                     | Genentech, Inc.                                 |   |                |
|                          | BD1                   | WO 97/44453   | 11-27-1997                     | Genentech, Inc.                                 |   |                |
|                          | BE1                   | WO 97/09427   | 03-13-1997                     | Genentech, Inc.                                 |   |                |
|                          | BF1                   | WO 94/10202   | 05-11-1994                     | Genentech, Inc.                                 |   |                |
|                          | BG1                   | WO 96/13518   | 05-09-1996                     | Genentech, Inc.                                 |   |                |
|                          | BH1                   | WO 99/17796   | 04-15-1999                     | Leukosite, Inc.                                 |   |                |
|                          | BI1                   | WO 2004/091375  | 10-28-2004                     | Medimmune, Inc.                                 |   |                |
|                          | BJ1                   | WO 2005/048917  | 06-02-2005                     | Medimmune, Inc.                                 |   |                |
|                          | BK1                   | WO 2005/051307  | 06-09-2005                     | Medimmune, Inc.                                 |   |                |
|                          | BL1                   | WO 03/094859  | 11-20-2003                     | Medimmune, Inc.                                 |   |                |
|                          | BM1                   | WO 96/09384   | 03-28-1996                     | President and Fellows of Harvard College        |   |                |
|                          | BN1                   | WO 2004/014292  | 02-19-2004                     | Purdue Research Foundation                      |   |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |                    |
|--|---|----|---|--------------------------|--------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    |   | <b>Complete if Known</b> |                    |
|  |   |    |   | Application Number       | 10/800350          |
|  |   |    |   | Filing Date              | March 12, 2004     |
|  |   |    |   | First Named Inventor     | Valery Krasnoperov |
|  |   |    |   | Art Unit                 | 1642               |
|  |   |    |   | Examiner Name            | S. E. Aeder        |
| Sheet  | 2 | of | 6 | Attorney Docket Number   | VASG-P01-002       |

|  |     |             |            |   |  |  |
|--|-----|-------------|------------|---|--|--|
|  | BO1 | WO 96/03043 | 02-08-1996 | Rutgers, the State University of New Jersey             |  |  |
|  | BP1 | WO 93/00425 | 01-07-1993 | The Walter and Eliza Hall Institute of Medical Research |  |  |
|  | BQ1 | EP 0999 278 | 05-10-2000 | Universite ParisVII                                     |  |  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS |                       |   |  |  |                |
|---------------------------------|-----------------------|---|--|--|----------------|
| Examiner Initials               | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   |  |  | T <sup>2</sup> |
|                                 | CG1                   | Adams, R.H., <i>et al.</i> , "Eph Receptors and Ephrin Ligands: Essential Mediators of Vascular Development," <i>Trends. Cardiovasc. Med.</i> , 10:183-188 (2000).  |  |  |                |
|                                 | CH1                   | Andres, A. C. <i>et al.</i> , "Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis," <i>Oncogene</i> , 9:1461-1467 (1994).  |  |  |                |
|                                 | CI1                   | Asahara, T. <i>et al.</i> , "Isolation of Putative Progenitor Endothelial Cells for Angiogenesis," <i>Science</i> , 275:964-967 (1997).   |  |  |                |
|                                 | CJ1                   | Batlle, E., <i>et al.</i> , "EphB receptor activity suppresses colorectal cancer progression," <i>Nature</i> , 435(23):1126-1130 (2005).  |  |  |                |
|                                 | CK1                   | Bennett, B. D. <i>et al.</i> , "Molecular cloning of a ligand for the EPH-related receptor protein-tyrosine kinase Htk," <i>Proc. Natl. Acad. Sci. USA</i> , 92:1866-1870 (1995).   |  |  |                |
|                                 | CL1                   | Bennett, B.D., <i>et al.</i> , "Cloning and Characterization of HTK, a Novel Transmembrane Tyrosine Kinase of the EPH Subfamily," <i>The Journal of Biological Chemistry</i> , 269(19): 14211-14218 (1994).   |  |  |                |
|                                 | CM1                   | Bergemann, A. D. <i>et al.</i> , "ELF-2, a New Member of the Eph Ligand Family Is Segmentally Expressed in Mouse Embryos in the Region of the Hindbrain and Newly Forming Somites," <i>Molecular and Cellular Biology</i> , 15(9):4921-4929 (1995).   |  |  |                |
|                                 | CN1                   | Bos <i>et al.</i> , "PD153035, a Tyrosine Kinase Inhibitor, Prevents Epidermal Growth Factor Receptor Activation and Inhibitors Growth of Cancer Cells in a Receptor Number-dependent Manner," <i>Clinical Cancer Research</i> , 3:2099-2106 (1997).  |  |  |                |
|                                 | CO1                   | Boyd, W.A., <i>et al.</i> , "Isolation and Characterization of a Novel Receptor-type Protein Tyrosine Kinase (hek) from a Human Pre-B Cell Line," <i>The Journal of Biological Chemistry</i> , 267(5):3262-3267 (1992).   |  |  |                |
|                                 | CP1                   | Brehmer <i>et al.</i> , "Cellular Targets of Gefitinib," <i>Cancer Research</i> , 65(2):379-382 (2005).   |  |  |                |
|                                 | CQ1                   | Bruckner <i>et al.</i> , "Tyrosine Phosphorylation of Transmembrane Ligands for Eph Receptors," <i>Science</i> , 275:1640-1643 (1997).  |  |  |                |
|                                 | CR1                   | Chang, M.W., <i>et al.</i> , "Adenovirus-Mediated Over-Expression of the Cyclin/Cyclin-Dependent Kinase Inhibitor, p21 Inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat Carotid Artery Model of Balloon Angioplasty," <i>J. Clin. Invest.</i> , 96:2260-2268 (1995). |  |  |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |                          |                        |              |
|---|---|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/> STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    | <b>Complete if Known</b> |                        |              |
|   |   |    | Application Number       | 10/800350              |              |
|   |   |    | Filing Date              | March 12, 2004         |              |
|   |   |    | First Named Inventor     | Valery Krasnoperov     |              |
|   |   |    | Art Unit                 | 1642                   |              |
|   |   |    | Examiner Name            | S. E. Aeder            |              |
| Sheet   | 3 | of | 6                        | Attorney Docket Number | VASG-P01-002 |

|     |   |
|-----|---|
| CS1 | Coffman, K.T., <i>et al.</i> , "Differential EphA2 Epitope Display on Normal versus Malignant Cells," <i>Cancer Research</i> , 63:7907-7912 (2003).   |
| CT1 | Dodelet, V.C. <i>et al.</i> , "Eph Receptors and Ephrin Ligands: Embryogenesis to Tumorigenesis," <i>Oncogene</i> , 19(49): 5614-19 (2000).   |
| CU1 | Durbin, L., <i>et al.</i> , "Eph signaling is required for segmentation and differentiation of the somites," <i>Genes &amp; Development</i> , 12:3096-3109 (1998).  |
| CV1 | Easty <i>et al.</i> , "Abnormal Protein Tyrosine Kinase Gene Expression During Melanoma Progression and Metastasis," <i>Int. J. Cancer</i> , 60:129-136 (1995).   |
| CW1 | Easty <i>et al.</i> , "Cytokine B61 as a growth factor for metastatic melanomas and increasing expression of its receptor ECK during melanoma progression," <i>Proceedings of the American Association for Cancer Research</i> , 35(356) (1994) abstract only.  |
| CX1 | Easty, <i>et al.</i> , "Expression of Eck and Lerk-1 During Melanoma Progression," <i>P137 St. George's Hospital Medical School, London, JK and Western Infirmary, Glasgow, UK, Collection of the National Library of Medicine by a third party.</i>            |
| CY1 | Feldman, L.J., <i>et al.</i> , "Perspectives of Arterial Gene Therapy for the Prevention of Restenosis," <i>Cardiovasc. Res.</i> , 32:194-207 (1996).   |
| CZ1 | Folkman <i>et al.</i> , "Angiogenic Factors," <i>Science</i> , 235:442-447 (1987).  |
| CA2 | Folkman, "Angiogenesis in cancer, vascular, rheumatoid and other disease," <i>Nature Medicine</i> , 1: 27-31, (1995).   |
| CB2 | Folkman, J. <i>et al.</i> , "Blood Vessel Formation: What Is Its Molecular Basis?" <i>Cell</i> , 87:1153-1155 (1996).   |
| CC2 | Folkman, J., "Angiogenic Therapy of the Human Heart," <i>Circulation</i> , 97(7): 628-29 (1998).  |
| CD2 | Folkman, J., "Antiangiogenic Gene Therapy," <i>Proc. Natl. Acad. Sci. USA.</i> , 95:9064-66 (1998).   |
| CE2 | Folkman, J., "Fighting Cancer by Attacking Its Blood Supply," <i>Sci. Am.</i> , 275(3): 150-54 (1996).  |
| CF2 | Gale, N.W. <i>et al.</i> , "Growth Factors Acting Via Endothelial Cell-Specific Receptor Tyrosine Kinases: VEGFs, Angiopoietins, and Ephrins in Vascular Development," <i>Genes Dev.</i> , 13:1055-66 (1999).   |
| CG2 | Gale, N.W., <i>et al.</i> , "Ephrin-B2 Selectively Marks Arterial Vessels and Neovascularization Sites in the Adult, with Expression in Both Endothelial and Smooth-Muscle Cells," <i>Dev. Biol.</i> , 230: 151-160 (2001).                                     |
| CH2 | GenBank Accession No. P52803.   |
| CI2 | Genetech's Response to Final Office Action on U.S. Patent Application Serial No. 09/442,898, filed March 29, 2002.  |
| CJ2 | Glassberg <i>et al.</i> , "Cultured endothelial cells derived from the human iliac arteries," <i>In Vitro</i> , 18:859-866 (1982).  |
| CK2 | Goetz <i>et al.</i> , "Long-term serial cultivation of arterial and capillary endothelium from adult bovine brain," <i>In Vitro Cellular and Developmental Biology</i> , 21:172-180 (1985).   |
| CL2 | Guzman, R.J., <i>et al.</i> , "In Vivo Suppression of Injury-Induced Vascular Smooth Muscle Cell Accumulation Using Adenovirus-Mediated Transfer of the Herpes Simplex Virus Thymidine Kinase Gene," <i>Proc. Natl. Acad. Sci. USA</i> , 91:10732-10736 (1994). |
| CM2 | Hafner <i>et al.</i> , "Differential Gene Expression of Eph Receptors and Ephrins in Benign Human Tissues and Cancers," <i>Clinical Chemistry</i> , 50(3):490-499 (2004).   |
| CN2 | Hafner, <i>et al.</i> , "Loss of Eph B6 expression in metastatic melanoma," <i>International Journal of Oncology</i> , 23:1553-1559 (2003).   |
| CO2 | Hausner, C., "Organogenesis Vascular Graft Becomes Physiologically-Responsive Living  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |                          |                        |              |
|--|---|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    | <b>Complete if Known</b> |                        |              |
|  |   |    | Application Number       | 10/800350              |              |
|  |   |    | Filing Date              | March 12, 2004         |              |
|  |   |    | First Named Inventor     | Valery Krasnoperov     |              |
|  |   |    | Art Unit                 | 1642                   |              |
|  |   |    | Examiner Name            | S. E. Aeder            |              |
| Sheet  | 4 | of | 6                        | Attorney Docket Number | VASG-P01-002 |

|     |  |  |  |
|-----|--|--|--|
|     |  | Tissue After Implantation [online], " <i>Nature Biotechnol.</i> , (1999).  |  |
| CP2 |  | Henkemeyer, M., <i>et al.</i> , "Nuk Controls Pathfinding of Commissural Axons in the Mammalian Central Nervous System," <i>Cell</i> , 86:35-46 (1996).  |  |
| CQ2 |  | Indolfi, C., <i>et al.</i> , "Inhibition of Cellular ras Prevents Smooth Muscle Cell Proliferation After Vascular Injury In Vivo," <i>Nature Med.</i> , 1(6):541-545 (1995).   |  |
| CR2 |  | Kenyon, B.M., <i>et al.</i> , "A Model of Angiogenesis in the Mouse Cornea," <i>Invest Ophthalmol. Vis. Sci.</i> , 37:1625-1632 (1996).  |  |
| CS2 |  | Keogh, M-C, <i>et al.</i> , "Design of a Muscle Cell-Specific Expression Vector Utilising Human Vascular Smooth Muscle ? - Actin Regulatory elements," <i>Gene Therapy</i> , 6:616-628 (1999).   |  |
| CT2 |  | Lackmann, <i>et al.</i> , "Distinct Subdomains of the EphA3 Receptor Mediate Ligand Binding and Receptor Dimerization," <i>The Journal of Biological Chemistry</i> , 273 (32):20228-20237 (1998).  |  |
| CU2 |  | Li, J., <i>et al.</i> , "Expression of the SM22x Promoter in Transgenic Mice Provides Evidence for Distinct Transcriptional Regulatory Programs in Vascular and Visceral Smooth Muscle Cells," <i>J. Cell Biol.</i> , 132:849-59 (1996).   |  |
| CV2 |  | Lin, P., <i>et al.</i> , "Antiangiogenic Gene Therapy Targeting the Endothelium-Specific Receptor Tyrosine Kinase Tie2," <i>Proc. Natl. Acad. Sci., USA</i> , 95:8829-8834 (1998).   |  |
| CW2 |  | Magal, <i>et al.</i> , "B61, a Ligand for the Eck Receptor Protein-Tyrosine Kinase, Exhibits Neurotrophic Activity in Cultures of Rat Spinal Cord Neurons," <i>Journal of Neuroscience Research</i> , 43:735-744 (1996).                   |  |
| CX2 |  | Maru, <i>et al.</i> , "Evolution, Expression, and Chromosomal Location of a Novel Receptor Tyrosine Kinase Gene, eph," <i>Molecular and Cellular Biology</i> , 8(9):3770-3776 (1998).  |  |
| CY2 |  | Maru, <i>et al.</i> , "Overexpression confers an oncogenic potential upon the eph gene," <i>Oncogene</i> , 5:445-447 (1990).   |  |
| CZ2 |  | Mellitzer, G., <i>et al.</i> , "Eph Receptors and Ephrins Restrict Cell Intermingling and Communication," <i>Nature</i> , 400:77-82 (1999).  |  |
| CA3 |  | Nakanuma, Y. <i>et al.</i> , "Succinylated Wheat Germ Agglutinin Lectin Binding in Intrahepatic Vessels: A New Histochemical Tool," <i>Arch. Pathol. Lab. Med.</i> , 117:809-811 (1993).   |  |
| CB3 |  | Niklason, L.E., <i>et al.</i> , "Functional Arteries Grown In Vitro," <i>Science</i> , 284:489-493 (1999).   |  |
| CC3 |  | Niklason, L.E., <i>et al.</i> , "Morphologic and Mechanical Characteristics of Engineered Bovine Arteries," <i>J. Vasc. Surg.</i> , 33:628-638 (2001).   |  |
| CD3 |  | Nikolova, <i>et al.</i> , "Cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrin-B2 during mammary gland morphogenesis," <i>Journal of Cell Science</i> , 111:2741-2751 (1998). |  |
| CE3 |  | Ogle <i>et al.</i> , "The Role of Vascular Smooth Muscle Cell Integrins in the Compaction and Mechanical Strengthening of a Tissue-Engineered Blood Vessel," <i>Tissue Engineering</i> , 5(4):387-402 (1999).                              |  |
| CF3 |  | Orioli, D., <i>et al.</i> , "Sek4 and Nuk Receptors Cooperate in Guidance of Commissural Axons and in Palate Formation," <i>Embo J.</i> , 15(22):6035-6049.  |  |
| CG3 |  | Pandey <i>et al.</i> , "Role of B61, the ligand for the eck receptor tyrosine kinase, in TNF- $\alpha$ -induced angiogenesis" <i>Science</i> , 268:567-569 (1996).   |  |
| CH3 |  | Parangi <i>et al.</i> , "Antiangiogenic therapy of transgenic mice impairs <i>de novo</i> tumor growth," <i>Proc. Natl. Acad. Sci. USA</i> , 93:2002-2007 (1996).  |  |
| CI3 |  | Peng <i>et al.</i> , "Regulation of Ca <sup>2+</sup> -activated K <sup>+</sup> channels in pulmonary vascular smooth muscle cells: role of nitric oxide," <i>J. Applied Physiol.</i> , 81:1264-1272 (1996).                                |  |
| CJ3 |  | Presta <i>et al.</i> , "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders," <i>Cancer Research</i> , 57:4593-   |  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

|  |   |    |                          |                        |              |
|--|---|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    | <b>Complete if Known</b> |                        |              |
|  |   |    | Application Number       | 10/800350              |              |
|  |   |    | Filing Date              | March 12, 2004         |              |
|  |   |    | First Named Inventor     | Valery Krasnoperov     |              |
|  |   |    | Art Unit                 | 1642                   |              |
|  |   |    | Examiner Name            | S. E. Aeder            |              |
| Sheet  | 5 | of | 6                        | Attorney Docket Number | VASG-P01-002 |

|  |     |  |  |
|--|-----|--|--|
|  |     | 4599 (1997).   |  |
|  | CK3 | Ramchandran <i>et al.</i> , "Metalloprotease-mediated cleavage secretion of pulmonary ACE by vascular endothelial and kidney epithelial cells," <i>Am. J. Physiology</i> , 271:H744-751 (1996).  |  |
|  | CL3 | Risau, W., "Mechanisms of angiogenesis," <i>Nature</i> , 386:671-674 (1997).   |  |
|  | CM3 | Shepard, <i>et al.</i> , "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic," <i>Journal of Clinical Immunology</i> , 11(3):117-127 (1991).   |  |
|  | CN3 | Simonet, S., <i>et al.</i> , "Venous and Arterial Endothelial Cells Respond Differently to Thrombin and its Endogenous Receptor Agonist," <i>European Journal of Pharmacology</i> , 216:135-137 (1992).                                  |  |
|  | CO3 | Simons, M., <i>et al.</i> , "Antisense c-myc Oligonucleotides Inhibit Intimal Arterial Smooth Muscle Cell Accumulation In Vivo," <i>Nature</i> , 359(6390):67-70 (1992).   |  |
|  | CP3 | Stein, E. <i>et al.</i> , "Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses," <i>Genes &amp; Development</i> , 12:667-678 (1998).                   |  |
|  | CQ3 | Stein, E. <i>et al.</i> , "Nck Recruitment to Eph Receptor, EphB1/ELK, Couples Ligand Activation to c-Jun Kinase," <i>The Journal of Biological Chemistry</i> , 273(3):1303-1308 (1998).   |  |
|  | CR3 | Sturz, <i>et al.</i> , "EphB4 signaling is capable of mediating ephrinB2-induced inhibition of cell migration," <i>Biochemical and Biophysical Research Communications</i> , 313:80-88 (2004).   |  |
|  | CS3 | Sunasse, <i>et al.</i> , "Tumour angiogenesis: Hitting cancer where it hurts," <i>Current Biology</i> , 7(5):R282-R285 (1997).   |  |
|  | CT3 | Tallquist, M.D., <i>et al.</i> , "Growth Factor Signaling Pathways in Vascular Development," <i>Oncogene</i> , 18(55):7917-7932 (1999).  |  |
|  | CU3 | The Eph Nomenclature Committee, "Unified Nomenclature for Eph Family Receptors and Their Ligands, the Ephrins," <i>Cell</i> , 90:403-404 (1997).   |  |
|  | CV3 | Thurston <i>et al.</i> , "Permeability-related changes revealed at endothelial cell borders in inflamed venules by lectin binding," <i>American Journal of Physiology</i> , 271:H2547-H2562 (1996).                                      |  |
|  | CW3 | Tsui, L.V., <i>et al.</i> , "p27-p16 Fusion Gene Inhibits Angioplasty-Induced Neointimal Hyperplasia and Coronary Artery Occlusion," <i>Circ. Res.</i> , 89:323-328 (2001).  |  |
|  | CX3 | Twardowski <i>et al.</i> , "Clinical trials of antiangiogenic agents," <i>Current Opinion in Oncology</i> , 9:584-589 (1997).  |  |
|  | CY3 | van de Wiel <i>et al.</i> , "Factors that define the susceptibility of endothelial cells to tumor necrosis factor and lipid A," <i>Immunopharmacology</i> , 23:49-56 (1992).   |  |
|  | CZ3 | Vasgene Therapeutics, Inc., "Statement of Grounds of Opposition," In the Matter of European Patent No. 1135153 (EP-B-1135153), (2006).   |  |
|  | CA4 | Vector Laboratories, "Wheat Germ Agglutinin (WGA)," [online]   |  |
|  | CB4 | von der Leyen, H.E., <i>et al.</i> , "Gene Therapy Inhibiting Neointimal Vascular Lesion: In Vivo Transfer of Endothelial Cell Nitric Oxide Synthase Gene," <i>Proc. Natl. Acad. Sci.</i> , 92:1137-1141 (1995).                         |  |
|  | CC4 | Wang <i>et al.</i> , "Molecular Distinction and Angiogenic Interactions Between Embryonic Arteries and Veins Revealed By EphrinB2 and Its Receptor EphB4," <i>Circulation: Melvin L. Marcus Young Investigator Award</i> , Abstract 341. |  |
|  | CD4 | Wang, H. U. <i>et al.</i> , "Eph Family Transmembrane Ligands Can Mediate Repulsive Guidance of Trunk Neural Crest Migration and Motor Axon Outgrowth," <i>Neuron</i> , 18:383-396 (1997).   |  |
|  | CE4 | Waugh, J.M., <i>et al.</i> , "Thrombomodulin Overexpression to Limit Neointima Formation," <i>Circulation</i> , 102:332-337 (2000).  |  |
|  | CF4 | Winlaw, "Angiogenesis in the Pathobiology and Treatment of Vascular and Malignant  |  |

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |                    |
|---|---|----|---|--------------------------|--------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |                    |
|   |   |    |   | Application Number       | 10/800350          |
|   |   |    |   | Filing Date              | March 12, 2004     |
|   |   |    |   | First Named Inventor     | Valery Krasnoperov |
|   |   |    |   | Art Unit                 | 1642               |
|   |   |    |   | Examiner Name            | S. E. Aeder        |
| Sheet   | 6 | of | 6 | Attorney Docket Number   | VASG-P01-002       |

|  |     |  |  |
|--|-----|--|--|
|  |     | Diseases," <i>Ann. Thorac. Surg.</i> , 64:1204-1211 (1997).  |  |
|  | CG4 | Xu, <i>et al.</i> , "Function of the Eph-related kinase rtk1 in patterning of the zebrafish forebrain," <i>Nature</i> , 381:19-322 (1996).   |  |
|  | CH4 | Yamamoto <i>et al.</i> , "Differences in Cellular Responses to Mitogens in Arterial Smooth Muscle Cells Derived From Patients With Moyamoya Disease," <i>Stroke</i> , 29:1188-1193 (1998). |  |
|  | CI4 | Yancopoulos, G. D. <i>et al.</i> , "Vasculogenesis, Angiogenesis, and Growth Factors: Ephrins Enter the Fray at the Border," <i>Cell</i> , 93:661-664 (1998).                              |  |
|  | CJ4 | Yuan, <i>et al.</i> , "Syndecan-1 up-regulated by ephrinB2/EphB4 plays dual roles in inflammatory angiogenesis," <i>Blood</i> , 104(4):1025-1033 (2004).                                   |  |
|  | CK4 | Zetter, "Angiogenesis and Tumor Metastasis," <i>Annu. Rev. Med.</i> , 49:407-424, (1998).  |  |
|  | CL4 | Zhang, X-Q, <i>et al.</i> , "Stromal Cells Expressing ephrin-B2 Promote the Growth and Sprouting of Ephrin-B2+ Endothelial Cells," <i>Blood</i> , 98:1028-37 (2001).                       |  |
|  | CM4 | Zhou, "The Eph Family Receptor and Ligands," <i>Pharmacol. Ther.</i> , 77(3) 151-181 (1998).   |  |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|





# IFW

PTO/SB/17 (12-04v2)  
Approved for use through 7/31/2006. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

|  |                    |                          |                    |
|--|--------------------|--------------------------|--------------------|
| <b>FEE TRANSMITTAL</b><br>For FY 2005  |                    | <b>Complete if Known</b> |                    |
|  |                    | Application Number       | 10/800350          |
|  |                    | Filing Date              | March 12, 2004     |
|  |                    | First Named Inventor     | Valery Krasnoperov |
|  |                    | Examiner Name            | S. E. Aeder        |
| <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27 | Art Unit           | 1642                     |                    |
| <b>TOTAL AMOUNT OF PAYMENT</b>   | <b>(\$)</b> 180.00 | Attorney Docket No.      | VASG-P01-002       |

|   |   |
|---|---|
| <b>METHOD OF PAYMENT</b> (check all that apply)   |   |
| <input type="checkbox"/> Check  | <input type="checkbox"/> Credit Card  |
| <input type="checkbox"/> Money Order  | <input type="checkbox"/> None   |
| <input type="checkbox"/> Other (please identify): _____   |   |
| <input checked="" type="checkbox"/> Deposit Account   | Deposit Account Number: 18-1945   |
| Deposit Account Name: Fish & Neave IP Group, Ropes & Gray LLP   |   |
| For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)                |   |
| <input checked="" type="checkbox"/> Charge fee(s) indicated below   | <input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee |
| <input checked="" type="checkbox"/> Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17 | <input checked="" type="checkbox"/> Credit any overpayments                       |

|   |                     |   |                                |                                  |                         |                     |                       |
|---|---------------------|---|--------------------------------|----------------------------------|-------------------------|---------------------|-----------------------|
| <b>FEE CALCULATION</b>  |                     |   |                                |                                  |                         |                     |                       |
| <b>1. BASIC FILING, SEARCH, AND EXAMINATION FEES</b>  |                     |   |                                |                                  |                         |                     |                       |
|   | <b>FILING FEES</b>  |   | <b>SEARCH FEES</b>             |                                  | <b>EXAMINATION FEES</b> |                     |                       |
|   |                     | <b>Small Entity</b>                                     |                                | <b>Small Entity</b>              |                         | <b>Small Entity</b> |                       |
| <b>Application Type</b>   | <b>Fee (\$)</b>     | <b>Fee (\$)</b>   | <b>Fee (\$)</b>                | <b>Fee (\$)</b>                  | <b>Fee (\$)</b>         | <b>Fee (\$)</b>     | <b>Fees Paid (\$)</b> |
| Utility   | 300                 | 150   | 500                            | 250                              | 200                     | 100                 |                       |
| Design  | 200                 | 100   | 100                            | 50                               | 130                     | 65                  |                       |
| Plant   | 200                 | 100   | 300                            | 150                              | 160                     | 80                  |                       |
| Reissue   | 300                 | 150   | 500                            | 250                              | 600                     | 300                 |                       |
| Provisional   | 200                 | 100   | 0                              | 0                                | 0                       | 0                   |                       |
| <b>2. EXCESS CLAIM FEES</b>   |                     |   |                                |                                  |                         |                     |                       |
| <b>Fee Description</b>  | <b>Fee (\$)</b>     | <b>Small Entity Fee (\$)</b>                            |                                |                                  |                         |                     |                       |
| Each claim over 20 (including Reissues)   | 50                  | 25  |                                |                                  |                         |                     |                       |
| Each independent claim over 3 (including Reissues)  | 200                 | 100   |                                |                                  |                         |                     |                       |
| Multiple dependent claims   | 360                 | 180   |                                |                                  |                         |                     |                       |
| <b>Total Claims</b>   | <b>Extra Claims</b> | <b>Fee (\$)</b>   | <b>Fee Paid (\$)</b>           | <b>Multiple Dependent Claims</b> |                         |                     |                       |
|   |                     | x   |                                | <b>Fee (\$)</b>                  | <b>Fee Paid (\$)</b>    |                     |                       |
| <b>Indep. Claims</b>  | <b>Extra Claims</b> | <b>Fee (\$)</b>   | <b>Fee Paid (\$)</b>           |                                  |                         |                     |                       |
|   |                     | x   |                                |                                  |                         |                     |                       |
| <b>3. APPLICATION SIZE FEE</b>  |                     |   |                                |                                  |                         |                     |                       |
| If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). |                     |   |                                |                                  |                         |                     |                       |
| <b>Total Sheets</b>   | <b>Extra Sheets</b> | <b>Number of each additional 50 or fraction thereof</b> | <b>Fee (\$)</b>                | <b>Fee Paid (\$)</b>             |                         |                     |                       |
|   | - 100 =             | /50   | (round up to a whole number) x |                                  |                         |                     |                       |
| <b>4. OTHER FEE(S)</b>  |                     |   |                                |                                  |                         |                     |                       |
| Non-English Specification, \$130 fee (no small entity discount)   |                     |   |                                |                                  |                         |                     | <b>Fees Paid (\$)</b> |
| Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement   |                     |   |                                |                                  |                         |                     | 180.00                |

|                     |               |                                   |                |
|---------------------|---------------|-----------------------------------|----------------|
| <b>SUBMITTED BY</b> |               |                                   |                |
| Signature           |               | Registration No. (Attorney/Agent) | 54,144         |
| Name (Print/Type)   | Z. Angela Guo | Telephone                         | (617) 951-7546 |
|                     |               | Date                              | June 14, 2006  |

|  |                                 |
|--|---------------------------------|
| I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below. |                                 |
| Dated: 6/14/06   | Signature: Dawn Class, D. Class |